Articles by Anthony J. DeStefano, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Anthony J. DeStefano, PhD

Anthony J. DeStefano, PhD


Anthony J. DeStefano, PhD, is vice-president, general chapters at the United States Pharmacopeial Convention.

Articles
Changing the Dynamic of CROs
October 2, 2013

Through its educational and networking opportunities, the American Association of Pharmaceutical Scientists plays an important role in partnering throughout the drug- development and commercialization process.

Inside USP: US Pharmacopeia Proposes New Standard on Glass Quality
June 2, 2012

US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.

Inside USP: A Holistic Approach to Supply-Chain Integrity
March 2, 2012

US Pharmacopeia documents best supply-chain practices and seeks broad input on proposal.

Inside USP: Global Harmonization Presents Opportunities and Challenges
January 2, 2012

To keep moving forward, the Pharmacopoeial Discussion Group needs industry participation.

Inside USP: Adulteration and Contamination Awareness
November 2, 2010

USP is working to ensure quality standards and to increase public information.

Inside USP: USP Metals Testing: A Workshop Report
November 2, 2008

Attendees at a recent workshop endorsed new methods to detect metals in drugs, dietary supplements, and food ingredients.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here